NASDAQ:TYRA Tyra Biosciences (TYRA) Stock Forecast, Price & News $13.95 +0.95 (+7.31%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$12.53▼$13.9550-Day Range$11.99▼$16.2252-Week Range$4.93▼$16.86Volume7,400 shsAverage Volume41,232 shsMarket Capitalization$593.71 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tyra Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside50.5% Upside$21.00 Price TargetShort InterestBearish8.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.04Based on 4 Articles This WeekInsider TradingSelling Shares$414,171 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.39) to ($1.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector675th out of 1,010 stocksPharmaceutical Preparations Industry341st out of 494 stocks 3.5 Analyst's Opinion Consensus RatingTyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Tyra Biosciences has a forecasted upside of 50.5% from its current price of $13.95.Amount of Analyst CoverageTyra Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.03% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 41.7, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently decreased by 0.69%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TYRA. Previous Next 2.8 News and Social Media Coverage News SentimentTyra Biosciences has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tyra Biosciences this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $414,171.00 in company stock.Percentage Held by Insiders18.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.60% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.39) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tyra Biosciences (NASDAQ:TYRA) StockTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.Read More Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TYRA Stock News HeadlinesMay 25, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Trading Down 4.7%May 24, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $14.45May 29, 2023 | Stocks To Trade (Ad)Free A.I. Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 23, 2023 | finance.yahoo.comWhat Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'May 22, 2023 | finance.yahoo.comWall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to TradeMay 17, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $12.40May 8, 2023 | markets.businessinsider.comWhere Tyra Biosciences Stands With AnalystsMay 5, 2023 | marketwatch.comTyra Biosciences Reports First Quarter 2023 Financial Results and HighlightsMay 29, 2023 | Stocks To Trade (Ad)Free A.I. Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 5, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Tyra Bioscience (TYRA)April 29, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Trading 21.5% Higher April 15, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Trading Up 8%April 7, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $15.67April 6, 2023 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells $32,320.00 in StockApril 1, 2023 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 2,407 SharesMarch 30, 2023 | americanbankingnews.comInsider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells 2,187 Shares of StockMarch 30, 2023 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) COO Daniel Bensen Sells 8,048 SharesMarch 30, 2023 | americanbankingnews.comTodd Harris Sells 2,779 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) StockMarch 29, 2023 | finance.yahoo.comTyra Biosciences to Participate in Upcoming Investor ConferencesMarch 29, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Sets New 52-Week High at $16.00March 29, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Tyra Biosciences, Inc. (NASDAQ:TYRA) Boosted by HC WainwrightMarch 28, 2023 | americanbankingnews.comOppenheimer Research Analysts Cut Earnings Estimates for Tyra Biosciences, Inc. (NASDAQ:TYRA)March 27, 2023 | finance.yahoo.comHere's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)March 26, 2023 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells $64,688.00 in StockMarch 26, 2023 | americanbankingnews.comTyra Biosciences' (TYRA) Buy Rating Reiterated at HC WainwrightMarch 26, 2023 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Expected to Earn Q1 2024 Earnings of ($0.40) Per ShareMarch 25, 2023 | americanbankingnews.comDaniel Bensen Sells 3,800 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TYRA Company Calendar Last Earnings3/22/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TYRA CUSIPN/A CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+50.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-19.89% Return on Assets-19.32% Debt Debt-to-Equity RatioN/A Current Ratio67.00 Quick Ratio67.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.11 per share Price / Book2.28Miscellaneous Outstanding Shares42,560,000Free Float34,731,000Market Cap$593.71 million OptionableNot Optionable Beta0.89 Key ExecutivesDr. Todd Harris Ph.D. (Age 43)Pres, CEO, Sec., Treasurer & Director Comp: $612.72kDr. Ronald V. Swanson Ph.D. (Age 59)Chief Scientific Officer Comp: $536.19kDr. Hiroomi Tada M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $519.65kMr. Daniel Bensen (Age 47)Co-Founder & COO Lynn SchermFin. DirectorMs. Esther van den Boom CPA (Age 42)CPA, Chief Financial Officer Dr. Robert L. Hudkins Ph.D. (Age 67)Chief Technology Officer Mr. Ali D. Fawaz J.D.Gen. Counsel & Sec.Ms. Sarah HonigVP of Corp. Devel. & StrategyDr. Piyush R. Patel Ph.D. (Age 57)Chief Devel. Officer More ExecutivesKey CompetitorsBelite BioNASDAQ:BLTEZymeworksNYSE:ZYMEJanux TherapeuticsNASDAQ:JANXArcutis BiotherapeuticsNASDAQ:ARQTLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 6,698 shares on 5/18/2023Ownership: 0.452%BVF Inc. ILBought 767,268 shares on 5/16/2023Ownership: 7.611%Geode Capital Management LLCBought 32,412 shares on 5/16/2023Ownership: 0.672%State Street CorpBought 15,463 shares on 5/16/2023Ownership: 0.545%HBK Sorce Advisory LLCBought 11,688 shares on 5/16/2023Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions TYRA Stock - Frequently Asked Questions Should I buy or sell Tyra Biosciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TYRA shares. View TYRA analyst ratings or view top-rated stocks. What is Tyra Biosciences' stock price forecast for 2023? 2 equities research analysts have issued twelve-month price targets for Tyra Biosciences' stock. Their TYRA share price forecasts range from $17.00 to $25.00. On average, they predict the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 50.5% from the stock's current price. View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts. How have TYRA shares performed in 2023? Tyra Biosciences' stock was trading at $7.60 at the start of the year. Since then, TYRA stock has increased by 83.6% and is now trading at $13.95. View the best growth stocks for 2023 here. When is Tyra Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our TYRA earnings forecast. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings data on Wednesday, March, 22nd. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.04. When did Tyra Biosciences IPO? (TYRA) raised $100 million in an IPO on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. What is Tyra Biosciences' stock symbol? Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA." Who are Tyra Biosciences' major shareholders? Tyra Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (7.61%), FMR LLC (7.40%), BlackRock Inc. (1.57%), Geode Capital Management LLC (0.67%), State Street Corp (0.55%) and JPMorgan Chase & Co. (0.45%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tyra Biosciences' stock price today? One share of TYRA stock can currently be purchased for approximately $13.95. How much money does Tyra Biosciences make? Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $593.71 million. The company earns $-55,330,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. How can I contact Tyra Biosciences? Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio.. This page (NASDAQ:TYRA) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.